Table 4.

Univariate and multivariate regression analysis to identify predictors for hepatotoxicity related to erlotinib administration in pancreatic cancer patients

Characteristics	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Male	0.957 (0.491–1.865)	1.279 (0.598–2.737)
Age ≥ 65	0.858 (0.444–1.656)	0.731 (0.369–1.448)
BSA ≥ 1.6a	0.652 (0.336–1.268)	0.549 (0.255–1.180)
CYP3A4 Inducer	3.690 (0.886–15.679)	4.114 (0.969–17.465)

For multivariate analysis, factors with p < 0.1 in the univariate analysis were included in addition to sex, age and BSA

BSA body surface area

^aThere was 1 missing data for BSA